AOP-Wiki

API

All KERs

Showing 3101 to 3125 of 3129 KERs

ID	Upstream Event	Downstream Event	Creation Date	Last Updated	AOPs

1498	1387: 7α-hydroxypregnenolone synthesis in the brain, decreased	1390: Sexual behavior, decreased	May 3, 2017	May 17, 2017	1 AOP 219: Inhibition of CYP7B activity leads to decreased reproductive success via decreased sexual behavior
3464	2250: HSD17B2 inhibition	2251: Increased E2 availability	Jan 2, 2025	Jan 2, 2025	1 AOP 565: 17β-Hydroxysteroid dehydrogenase 2, inhibition leading to activation, estrogen receptor alpha
2158	1796: 11β-hydroxylase inhibition	1756: Decreased, 11KT	Jul 13, 2020	Oct 3, 2025	None
2275	1796: 11β-hydroxylase inhibition	1835: Cortisol and 11β-(OH) testosterone decreased	Feb 9, 2021	Feb 9, 2021	1 AOP 349: Inhibition of 11β-hydroxylase leading to decresed population trajectory
312	281: T4 in serum, Decreased	280: T4 in neuronal tissue, Decreased	Nov 29, 2016	Apr 4, 2019	7 AOPs 42: Inhibition of Thyroperoxidase and Subsequent Adverse Neurodevelopmental Outcomes in Mammals 65: XX Inhibition of Sodium Iodide Symporter and Subsequent Adverse Neurodevelopmental Outcomes in Mammals 134: Sodium Iodide Symporter (NIS) Inhibition and Subsequent Adverse Neurodevelopmental Outcomes in Mammals 54: Inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment 8: Upregulation of Thyroid Hormone Catabolism via Activation of Hepatic Nuclear Receptors, and Subsequent Adverse Neurodevelopmental Outcomes in Mammals 458: AhR activation in the liver leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals 459: AhR activation in the thyroid leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals
403	281: T4 in serum, Decreased	402: Cognitive function, decreased	Nov 29, 2016	Apr 27, 2026	4 AOPs 42: Inhibition of Thyroperoxidase and Subsequent Adverse Neurodevelopmental Outcomes in Mammals 65: XX Inhibition of Sodium Iodide Symporter and Subsequent Adverse Neurodevelopmental Outcomes in Mammals 134: Sodium Iodide Symporter (NIS) Inhibition and Subsequent Adverse Neurodevelopmental Outcomes in Mammals 458: AhR activation in the liver leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals
1039	281: T4 in serum, Decreased	1007: Reduced, Anterior swim bladder inflation	Nov 29, 2016	Oct 10, 2022	1 AOP 159: Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation
1143	281: T4 in serum, Decreased	1093: Decreased, Thyroxine (T4) in tissues	Nov 29, 2016	Sep 3, 2020	None
1387	281: T4 in serum, Decreased	756: Hippocampal gene expression, Altered	Mar 24, 2017	Aug 11, 2018	1 AOP 42: Inhibition of Thyroperoxidase and Subsequent Adverse Neurodevelopmental Outcomes in Mammals
1388	281: T4 in serum, Decreased	757: Hippocampal anatomy, Altered	Mar 24, 2017	Aug 11, 2018	1 AOP 42: Inhibition of Thyroperoxidase and Subsequent Adverse Neurodevelopmental Outcomes in Mammals
1389	281: T4 in serum, Decreased	758: Hippocampal Physiology, Altered	Mar 24, 2017	Aug 11, 2018	1 AOP 42: Inhibition of Thyroperoxidase and Subsequent Adverse Neurodevelopmental Outcomes in Mammals
2038	281: T4 in serum, Decreased	1003: Decreased, Triiodothyronine (T3)	Feb 19, 2020	Oct 10, 2022	4 AOPs 159: Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation 363: Thyroperoxidase inhibition leading to altered visual function via altered retinal layer structure 364: Thyroperoxidase inhibition leading to altered visual function via decreased eye size 365: Thyroperoxidase inhibition leading to altered visual function via altered photoreceptor patterning
2168	281: T4 in serum, Decreased	1101: Altered, Amphibian metamorphosis	Aug 25, 2020	Aug 25, 2020	8 AOPs 175: Thyroperoxidase inhibition leading to altered amphibian metamorphosis 176: Sodium Iodide Symporter (NIS) Inhibition leading to altered amphibian metamorphosis 194: Hepatic nuclear receptor activation leading to altered amphibian metamorphosis 366: Competitive binding to thyroid hormone carrier protein transthyretin (TTR) leading to altered amphibian metamorphosis 367: Competitive binding to thyroid hormone carrier protein thyroid binding globulin (TBG) leading to altered amphibian metamorphosis 188: Iodotyrosine deiodinase (IYD) inhibition leading to altered amphibian metamorphosis 192: Pendrin inhibition leading to altered amphibian metamorphosis 193: Dual oxidase (DUOX) inhibition leading to altered amphibian metamorphosis
2420	281: T4 in serum, Decreased	753: Increase, Thyroid-stimulating hormone (TSH)	Jul 7, 2021	Jul 7, 2021	None
2422	281: T4 in serum, Decreased	1023: Increased, Thyroid-stimulating hormone (TSH)	Jul 7, 2021	Jul 7, 2021	3 AOPs 162: Enhanced hepatic clearance of thyroid hormones leading to thyroid follicular cell adenomas and carcinomas in the rat and mouse 110: Inhibition of iodide pump activity leading to follicular cell adenomas and carcinomas (in rat and mouse) 119: Inhibition of thyroid peroxidase leading to follicular cell adenomas and carcinomas (in rat and mouse)
2473	281: T4 in serum, Decreased	818: Occurrence, Cytoplasmic vacuolization (Renal tubule)	Sep 9, 2021	Sep 9, 2021	1 AOP 128: Kidney dysfunction by decreased thyroid hormone
2474	281: T4 in serum, Decreased	823: Occurrence, Cystic dilatation (renal tubule)	Sep 9, 2021	Sep 9, 2021	1 AOP 128: Kidney dysfunction by decreased thyroid hormone
2475	281: T4 in serum, Decreased	824: Occurrence, Cytoplasmic vacuolization (podocyte)	Sep 9, 2021	Sep 9, 2021	1 AOP 128: Kidney dysfunction by decreased thyroid hormone
2865	281: T4 in serum, Decreased	2119: Increase, Insulin resistance	Apr 3, 2023	Apr 20, 2023	1 AOP 457: Succinate dehydrogenase inhibition leading to increased insulin resistance through reduction in circulating thyroxine
3354	2265: Oligodendrocyte death, increased	2266: Demyelination, increased	Oct 1, 2024	Oct 1, 2024	2 AOPs 543: Inhibition of neuropathy target esterase leading to delayed neuropathy via lysolecithin cell membrane integration 544: Inhibition of neuropathy target esterase leading to delayed neuropathy via increased inflammation
3351	2262: NTE, inhibited	2263: LPS, increased	Oct 1, 2024	Oct 1, 2024	2 AOPs 543: Inhibition of neuropathy target esterase leading to delayed neuropathy via lysolecithin cell membrane integration 544: Inhibition of neuropathy target esterase leading to delayed neuropathy via increased inflammation
1331	1253: MLL translocation	1254: IFL	Jan 20, 2017	Aug 1, 2022	1 AOP 202: Inhibitor binding to topoisomerase II leading to infant leukaemia
3352	2263: LPS, increased	2264: LPS cell membrane integration, increased	Oct 1, 2024	Oct 1, 2024	1 AOP 543: Inhibition of neuropathy target esterase leading to delayed neuropathy via lysolecithin cell membrane integration
3356	2263: LPS, increased	149: Increase, Inflammation	Oct 1, 2024	Oct 1, 2024	1 AOP 544: Inhibition of neuropathy target esterase leading to delayed neuropathy via increased inflammation
3353	2264: LPS cell membrane integration, increased	2265: Oligodendrocyte death, increased	Oct 1, 2024	Oct 1, 2024	1 AOP 543: Inhibition of neuropathy target esterase leading to delayed neuropathy via lysolecithin cell membrane integration

Key Event Relationships (KERs)

All KERs